Wu, B., & Ma, F. (2020). Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer. Ther Adv Med Oncol.
Style de citation ChicagoWu, Bin, et Fei Ma. "Cost-effectiveness of Adding Atezolizumab to First-line Chemotherapy in Patients With Advanced Triple-negative Breast Cancer." Ther Adv Med Oncol 2020.
Style de citation MLAWu, Bin, et Fei Ma. "Cost-effectiveness of Adding Atezolizumab to First-line Chemotherapy in Patients With Advanced Triple-negative Breast Cancer." Ther Adv Med Oncol 2020.
Attention : ces citations peuvent ne pas être correctes à 100%.